FoodMarble

High-Level Overview

FoodMarble is a digital health company developing handheld breath analysis devices and a companion app to track personal digestive health, primarily targeting individuals with IBS, SIBO, and food intolerances, as well as healthcare professionals.[1][2][4] The devices measure hydrogen and methane gases in breath to quantify fermentation from undigested foods like FODMAPs, enabling users to log meals, symptoms, stress, and sleep for personalized insights that reduce bloating and discomfort—85% of users report symptom relief.[4][6][7] Initially direct-to-consumer, the company has expanded into medical devices used by over 1,000 U.S. healthcare providers, with strong growth including €8 million in funding, clinical validations at Johns Hopkins, and generative AI features in development.[1][4]

Origin Story

Founded in 2016 in Dublin, Ireland, FoodMarble emerged from a personal need: co-founder and CEO Aonghus Shortt built a prototype in 2015 for his wife, who struggled with gut symptoms, helping her identify compatible foods.[3][4] Shortt, alongside co-founders including Chief Medical Officer Dr. James Brief (a gastroenterologist), launched a 2017 pre-order campaign that attracted over 8,000 backers worldwide, funding the 2018 release of AIRE 1—the first consumer hydrogen breath tester based on clinical techniques.[3][4] Pivotal moments include the 2022 launch of AIRE 2 (adding methane detection) and MedAIRE 2 for physicians, 2024's Johns Hopkins clinical trial publication on SIBO monitoring, and 2025's second publication validating self-led diet personalization.[4][5]

Core Differentiators

• Advanced Sensing Technology: AIRE 2 measures both hydrogen (early fermentation/SIBO indicator) and methane (produced by two-thirds of people, linked to discomfort), validated against clinical devices with 100% agreement for carbohydrate absorption and lactose malabsorption detection.[4][5][6]
• Personalized App Insights: Integrates meal logging (with FODMAP library and barcode scanning), symptom tracking, stress/sleep data, and real-time feedback; new generative AI interprets data for users and clinicians.[1][6][7]
• Accessibility and Portability: Pocket-sized, at-home alternative to clinic tests, with Food Intolerance Kit for fructose, lactose, inulin, and sorbitol; used by consumers and 1,000+ U.S. providers.[4][6][7]
• Clinically Proven: Backed by independent validations, Johns Hopkins trials, and gastroenterologist oversight, shifting from DTC to B2B medical adoption.[4][6]

Role in the Broader Tech Landscape

FoodMarble rides the digital therapeutics and personalized nutrition wave in the $50B+ gut health market, where 10-20% of people suffer IBS/SIBO amid rising demand for non-invasive, data-driven tools post-COVID.[1][2][4] Timing aligns with wearable health tech proliferation (e.g., continuous glucose monitors) and AI-enhanced consumer diagnostics, making clinic-grade breath testing portable and scalable—evident in its multichannel pivot and clinician adoption.[1][4] It influences the ecosystem by democratizing digestive research, partnering with investors like Business Venture Partners (EIIS Fund), and publishing evidence that supports at-home monitoring, potentially reducing healthcare burdens while fueling food tech innovation.[2][4]

Quick Take & Future Outlook

FoodMarble is poised for expansion with generative AI rollouts, further clinical integrations, and global clinician networks beyond its 1,000+ U.S. providers, capitalizing on self-led gut health trends.[1][4] Rising AI diagnostics, FODMAP-aware consumer products, and SIBO/IBS awareness will propel growth, evolving it from a personal tracker to a platform influencing personalized medicine. This positions FoodMarble as a leader in accessible digestive tech, transforming individual relief into systemic health insights.